Małkowski, M.; Almgren-Rachtan, A.; Olszanecka-Glinianowicz, M.; Chudek, J.; Chłosta, P.
Regular and Irregular Use and Reasons for Discontinuation of Solifenacin Therapy in Patients with Overactive Bladder Managed by Urologists. Pharmaceuticals 2024, 17, 116.
https://doi.org/10.3390/ph17010116
AMA Style
Małkowski M, Almgren-Rachtan A, Olszanecka-Glinianowicz M, Chudek J, Chłosta P.
Regular and Irregular Use and Reasons for Discontinuation of Solifenacin Therapy in Patients with Overactive Bladder Managed by Urologists. Pharmaceuticals. 2024; 17(1):116.
https://doi.org/10.3390/ph17010116
Chicago/Turabian Style
Małkowski, Mateusz, Agnieszka Almgren-Rachtan, Magdalena Olszanecka-Glinianowicz, Jerzy Chudek, and Piotr Chłosta.
2024. "Regular and Irregular Use and Reasons for Discontinuation of Solifenacin Therapy in Patients with Overactive Bladder Managed by Urologists" Pharmaceuticals 17, no. 1: 116.
https://doi.org/10.3390/ph17010116
APA Style
Małkowski, M., Almgren-Rachtan, A., Olszanecka-Glinianowicz, M., Chudek, J., & Chłosta, P.
(2024). Regular and Irregular Use and Reasons for Discontinuation of Solifenacin Therapy in Patients with Overactive Bladder Managed by Urologists. Pharmaceuticals, 17(1), 116.
https://doi.org/10.3390/ph17010116